Recently, many new diagnostic biomarkers have been developed for colorectal cancer.
We chose 2 reliable methods with established techniques and simple procedures, the detection of serum microRNA and metabolomics based on gas chromatography/mass spectrometry (GC/MS), to validate their diagnostic value and attempt to develop appropriate models.
MicroRNA are small, non-protein-coding RNA molecules that regulate gene expression at the post-transcriptional level. 7 Over the past decade, studies have shown that diverse microRNA have great potential for the diagnosis of CRC. However, the diagnostic accuracy is inconsistent among these studies. It is, thus, essential to review the diagnostic value of each microRNA through a meta-analysis. We performed the abovementioned work and then selected 5 microRNA with satisfactory Youden indexes or area under the curve (AUC) values of the receiver operating curve (ROC) to establish a diagnostic panel.
Metabolomics is defined as the quantitative measurement of low-molecular-weight metabolites in an organism at a specified time under specific environmental conditions. 8 Among the various metabolomics techniques, including GC/MS, nuclear magnetic resonance (NMR), high-performance liquid chromatography/mass spec-
trometry (HPLC/MS) and Fourier transform infrared (FT/IR)
spectroscopy, GC/MS is a robust metabolomic tool and is widely used in metabolite identification based on its high sensitivity, peak resolution and reproducibility. 9, 10 Several studies have indicated a high diagnostic value for CRC, and the AUC is usually more than 0.90. 5, 11, 12 Our study further validated the diagnostic accuracy of metabolomics and compared the most frequently used statistical methods.
| MATERIALS AND METHODS

| Study design
First, we reviewed the diagnostic value of each microRNA mentioned in previous studies. We retrieved reports from PubMed, Next, we selected 25 patients and 30 HC from the cohort mentioned above using a completely random method and used GC/MS to profile the metabolomic signatures. Finally, the diagnostic efficiencies were compared among the new models and the traditional tumor biomarkers CEA and carbohydrate antigen (CA19-9). The flow-process diagram for the literature is presented in Figure S1 . 
| Data extraction
Two reviewers independently extracted the following data from all the included articles: (i) basic characteristics of the studies, including the first author, year of publication, country of origin, ethnicity, sample size, mean age, male ratio, type of specimens (serum or plasma), target microRNA and reference control; and (ii) diagnostic information of the microRNA, including variation trend of the expression, sensitivity, specificity and AUC.
| Patients and specimens
In this study, we included 85 patients with CRC and 78 HC who CRC patients' diagnosis was confirmed by pathological biopsy.
Patients were excluded if they had other malignant tumors or had undergone a surgical operation, radiotherapy or chemotherapy.
Healthy individuals were identified by clinical manifestations, histories of disease and results of blood tests. The serum samples were centrifuged in microfuge tubes for 10 minutes at 820 g and 4°C to remove residual cell debris, and the supernatants were immediately stored at À80°C until use. The concentrations of serum CEA and CA19-9 were measured using an electro-chemiluminescence immunoassay.
The protocol was approved by the Ethics Committee of Zhongshan Hospital of Fudan University, Shanghai. Written informed consent was obtained from all participants.
| RNA extraction and reverse transcription
A total of 200 lL of the serum samples was spiked with 2 lL of 25 fmol synthetic cel-miR-39 (Tiangen, Beijing, China) as the external reference. Total RNA from the serum samples was isolated simultaneously using the miRcute microRNA Isolation Kit from Tiangen following the manufacturer's instructions. 13 To determine the concentrations and purities, the optical density of the extracted total RNA was assessed at 260 and 280 nm on a NanoDrop spectrophotometer (NanoDrop, Wilmington, DE, USA).
The extracted microRNA was polyadenylated by poly (A) polymerase in a 20-lL volume, and 6 lL of the poly (A) reaction solution was reverse-transcribed to cDNA in another 20 lL using miRcute 
| Gas chromatography/mass spectrometry analysis
The GC/MS analysis was performed on an Agilent 6980 GC system equipped with a fused-silica capillary column (internal diameter: 30 m 9 0.25 mm) with a 0.25-lm HP-5MS stationary phase (Agilent, Shanghai, China). We used the same operational methods as in our previous studies. 14 
| Statistical analyses
The statistical analyses were performed using Stata 12.0 (StataCorp LP, College Station, TX, USA), R software 3.3.3 (R Foundation for Statistical Computing, Vienna, Austria) and SIMCA-P 13.0 (Umetrics AB, Umea, Vasterbotten, Sweden). The level of significance was set at P < .05.
Meta-analysis methods were used to assess the accuracy of the individual microRNA to diagnose CRC using the sensitivity, specificity, Youden index and AUC of the summary receiver operator characteristic (SROC). Deeks' funnel plot was used to evaluate the publication bias of the included studies; P < .05 indicates a significant publication bias. 
| Study selection and literature characteristics
A total of 867 records from the database search were initially identified, of which 315 were from PubMed, 366 were from Embase and 186 were from CBM. After removing 196 duplicates, 600 irrelevant studies and 9 articles that failed to provide enough diagnostic information, 62 published studies were finally included in this systematic review (Table S1 ). Table S2 .
| Diagnostic value of microRNA in the literature
There were 63 microRNA mentioned in the included articles, of which 45 were studied in a single article. We conducted the metaanalyses to represent the diagnostic accuracy of the other 18 micro-RNA. The details regarding these microRNA are presented in Table 1 .
| Publication bias
Publication bias was evaluated using Deeks' funnel plot ( Figure S2 ), and the Deeks' test returned a P-value of .34, which revealed no significant publication bias in this analysis.
| Study population
The clinical and pathological features of the patients and HC are displayed in Table 2 . Age was significantly different between the CRC patients and the HC. Thus, we conducted a covariance analysis. The expression of the microRNA and the scores of the components of the metabolomics performed were the dependent variables. The covariates were age and group, including patients or HC. We found that age was unrelated to the expression of the microRNA and the scores of the components (P < .05).
| Expression of microRNA
MiR-21, miR-29a, miR-92a, miR-125b and miR-223 were selected because of their high AUC values or Youden indexes in previous studies. The results of the qRT-PCR indicated that the serum levels of the 5 microRNA in the CRC patients were significantly higher than those in the HC (Wilcoxon-Mann-Whitney test, P < .001) (Table S3 and Figure 1) . The subgroup analyses showed that there were no significant differences in the expression of the 5 microRNA among different TNM stages (Kruskal-Wallis test, P > .05) ( Figure S3A ).
| Diagnostic models established using microRNA
We calculated the cut-off value, sensitivity, specificity, Youden index and AUC of each microRNA and their combinations to find the The upregulated or downregulated expression trend in the colorectal cancer (CRC) patients vs the healthy control (HC) group. The data on the sensitivity, specificity and area under the curve (AUC) were obtained through the meta-analysis when the number of included articles was more than one.
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| 1189 optimal diagnostic model ( Table 3 Figure S4A shows, the values for microRNA of CRC patients calculated using the formula were significantly decreased after surgery (paired t test, P < .001) and were close to those of HC (Student's t test, P = .237).
| Discrepant metabolites and total ion chromatogram
In total, 1118 features were extracted in this experiment. The significantly different metabolites are shown in Table S4 . RT was stable with no drift in any of the peaks of the total ion chromatograms (TIC), which indicated that the results were reliable.
| Diagnostic models established using metabolomics
In the PCA model, we extracted 8 principal components whose eigenvalue was equal to or more than 1.0. We calculated the diag- of healthy people, the sensitivity was 15.5%, and the specificity was 100%.
The ROC curves of the new models and the traditional tumor biomarkers are shown in Figure 3 . MicroRNA as diagnostic biomarkers have advantages and disadvantages. Different from mRNA, microRNA are stable at room temperature. The expression of serum microRNA is stable even after repeated freeze-thawing. 26 Compared with a colonoscopy and a biopsy, a serum test is non-invasive. However, nucleic acids cannot be detected directly; they must first be extracted, and, as a result, nucleic acid detection cannot be automated currently. Each sample detection for 4 microRNA costs approximately US$23 in China, while the detection of CEA and CA19-9 costs US$4.6 and US$8.0 dollars, respectively. In addition, due to the choice of internal/ external references, the dosage of reagents and an operating process that is not yet standardized, the cut-off value cannot be unified.
T A B L E 2 Clinical characteristics of the study population
Therefore, the standardization of protocols and methodologies is necessary to achieve clinical application.
Serum microRNA increase in various malignant tumors. 27 In addition, some researchers propose that the specificity is not as high as reported by most diagnostic tests. However, it is better that diagnostic models of microRNA be used to indicate whether a patient may be suffering from a malignant tumor. A position diagnosis can be completed through typical clinical manifestations, digital rectal examination and colonoscopy.
As expected, our study validated the excellent diagnostic efficiency of metabolomics. Metabolomics, as a high-throughput technique, detects the contents of thousands of types of low-molecularweight metabolites. Compared with the standard detection methods of each metabolite, GC/MS may have a lower accuracy. Nevertheless, the GC/MS analysis reflects the signature of whole body metabolism and can provide more information to establish diagnostic models. In this study, we utilized all detected metabolites, not only the significantly different metabolites, to expand the applications.
The results shown in Table 4 imply that a model with OPLS-DA has the highest AUC, and a model with PLS-DA ranks second before one using PCA when including the same number of components because PLS-DA and OPLS-DA are supervisory analysis methods, while PCA is non-supervisory. Based on PLS, OPLS separates the orthogonal variables unrelated to the Y matrix by an orthogonal signal correction. 28, 29 The models established by these 3 statistical methods are still stable when the variables are numerous and the observations are sparse. Although the diagnostic efficiency of PCA was worse than that of PLD-DA and OPLS-DA when including the same number of components, the PCA extracted more principal components to increase the AUC.
The advantages of GC/MS are not only its high diagnostic value.
Our preliminary experiment indicated that different malignant tumors could be divided by metabolomics because it appears that the metabolic spectra are distinct in different malignant tumors. The US$72.5
testing fee of each sample is an affordable price in China. However, the pretreatment process is not standardized, including the choice of the internal standard and derivatization reagents, the operating order and the time of each step.
In conclusion, there is no doubt that the diagnostic efficiencies of the new models are higher than those of the traditional biomarkers CEA and CA19-9. The application of the ROC curve also increases the Youden index compared with the traditional diagnosis method, whose cut-off value is determined as the upper bound of 95% of healthy people. We suggest that a GC/MS analysis and a combination of microRNA allow for a diagnosis of CRC.
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